MedTrace Logo

Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis

NCT02456363 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2015-05-28

No results posted yet for this study

Summary

Assessed using (1) Adalimumab(Humira) and NSAIDs (2) Use only Adalimumab(Humira) treatment of ankylosing spondylitis patient safety and efficacy.

Conditions

Interventions

BIOLOGICAL

TNF alpha

Depending on patient need to use different TNF alpha

DRUG

NSAIDs and sulfasalazine

randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)

Sponsors & Collaborators

  • Chung Shan Medical University

    lead OTHER

Principal Investigators

  • Wei C- C, M.D. · Chung Shan Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2019-10-31
Completion
2019-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02456363 on ClinicalTrials.gov